ESSA PHARMA, INC.
5.10%
2,262,026
1633932
29668H708
Apr 22, 2025
Apr 23, 2025, 09:45 PM
Reporting Persons (6)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| SOLEUS CAPITAL MASTER FUND, L.P. | Partnership | 5.10% | 2,262,026 | 0 | 2,262,026 |
| SOLEUS CAPITAL, LLC | Other | 5.10% | 2,262,026 | 0 | 2,262,026 |
| SOLEUS CAPITAL GROUP, LLC | Other | 5.10% | 2,262,026 | 0 | 2,262,026 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | Partnership | 5.10% | 2,262,026 | 0 | 2,262,026 |
| SOLEUS GP, LLC | Other | 5.10% | 2,262,026 | 0 | 2,262,026 |
| GUY LEVY | Individual | 5.10% | 2,262,026 | 0 | 2,262,026 |
Disclosure Items (3)
Common Stock
ESSA PHARMA, INC.
Suite 720, 999 West Broadway, British Columbia, A1, V5Z 1K5
Master Fund has entered into cash settled swap transactions with respect to which it receives payments calculated by reference to the rate of return on Common Stock in exchange for payments by Master Fund to the swap counterparty equal to a fixed or floating interest rate on the notional amount of the swap. As of the date of this Amendment, these swaps reflect economic exposure to an aggregate of 4,025,351 shares of Common Stock. Master Fund does not obtain any beneficial ownership of the Common Stock (including the power to vote or direct the voting, or dispose or direct the disposition, of the shares of Common Stock that are subject to the swaps) or any right to obtain the Common Stock in connection with these swap transactions, and may enter into additional swap transactions or terminate existing swap transactions at any time. As a result, the Reporting Persons disclaim beneficial ownership of the shares of Common Stock that are subject to the swaps transactions. Other than the Joint Filing Agreement attached as Exhibit 1 to the original Schedule 13D, or as otherwise described herein, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons and between such persons and any person with respect to any securities of the Issuer.
1. Joint Filing Agreement, dated April 15, 2025, among the Reporting Persons. (#) 2. Letter dated April 15, 2025 from Soleus Capital Management, L.P. to the Board of Directors of the Issuer. (#) # Previously filed as an exhibit to the original Schedule 13D filed by the Reporting Persons on April 15, 2025.